Literature DB >> 20170929

Plasma interleukin-1β concentrations are closely associated with fasting blood glucose levels in healthy and preclinical middle-aged nonoverweight and overweight Japanese men.

Yasumi Misaki1, Rie Miyauchi, Kazuki Mochizuki, Satsuki Takabe, Masaya Shimada, Yoko Ichikawa, Toshinao Goda.   

Abstract

Plasma interleukin (IL)-1β and IL-6 are markers that predict the risk of inflammation in diabetes. In the current study, we examined the relationship between fasting glucose and plasma inflammatory cytokines (IL-1β and IL-6) concentrations in healthy and preclinical middle-aged Japanese men (mean ± SD, 58.7 ± 7.8 years old) divided according to body mass index (<25 kg/m(2), nonoverweight group; ≥25 kg/m(2), overweight group). We conducted a cross-sectional study of 413 healthy and preclinical men aged 40 to 69 years who participated in health checkups in Japan. We measured their clinical parameters, lifestyle factors, and plasma IL-1β and IL-6 concentrations. Participants were classified according to their fasting blood glucose levels, and we compared their plasma cytokine levels. Plasma IL-1β and IL-6 levels in nonoverweight subjects were positively and strongly associated with fasting blood glucose and hemoglobin A(1c); in contrast, these cytokines were strongly associated with homeostasis model assessment of insulin resistance and fasting glucose in overweight subjects. Significant positive associations between plasma IL-1β and glucose concentrations were observed within the groups classified according to glucose concentrations, after adjustment for age and body mass index. The results of our current study show that plasma IL-1β levels are strongly associated with fasting blood glucose concentrations in healthy and preclinical nonoverweight and overweight Japanese men.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170929     DOI: 10.1016/j.metabol.2010.01.011

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Principal component 1 score calculated from metabolic syndrome diagnostic parameters is a possible marker for the development of metabolic syndrome in middle-aged Japanese men without treatment for metabolic diseases.

Authors:  Kazuki Mochizuki; Rie Miyauchi; Yasumi Misaki; Yoko Ichikawa; Toshinao Goda
Journal:  Eur J Nutr       Date:  2011-12-09       Impact factor: 5.614

Review 2.  Biological basis of depression in adults with diabetes.

Authors:  Shivam Champaneri; Gary S Wand; Saurabh S Malhotra; Sarah S Casagrande; Sherita Hill Golden
Journal:  Curr Diab Rep       Date:  2010-12       Impact factor: 4.810

3.  Self-reported faster eating is positively associated with accumulation of visceral fat in middle-aged apparently healthy Japanese men.

Authors:  Kazuki Mochizuki; Masami Yamada; Rie Miyauchi; Yasumi Misaki; Nobuhiko Kasezawa; Kazushige Tohyama; Toshinao Goda
Journal:  Eur J Nutr       Date:  2013-11-21       Impact factor: 5.614

4.  Interleukin-1 signaling contributes to acute islet compensation.

Authors:  Catherine Hajmrle; Nancy Smith; Aliya F Spigelman; Xiaoqing Dai; Laura Senior; Austin Bautista; Mourad Ferdaoussi; Patrick E MacDonald
Journal:  JCI Insight       Date:  2016-04-07

Review 5.  Innate immune activation in obesity.

Authors:  Carey N Lumeng
Journal:  Mol Aspects Med       Date:  2012-10-13

Review 6.  The mechanisms linking adiposopathy to type 2 diabetes.

Authors:  Jichun Yang; Jihong Kang; Youfei Guan
Journal:  Front Med       Date:  2013-10-01       Impact factor: 4.592

7.  Glucose starvation and hypoxia, but not the saturated fatty acid palmitic acid or cholesterol, activate the unfolded protein response in 3T3-F442A and 3T3-L1 adipocytes.

Authors:  Adina D Mihai; Martin Schröder
Journal:  Adipocyte       Date:  2015-01-12       Impact factor: 4.534

Review 8.  Innate Immunity Mediated Inflammation and Beta Cell Function: Neighbors or Enemies?

Authors:  Antonio Citro; Francesco Campo; Erica Dugnani; Lorenzo Piemonti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-08       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.